S J Ryan Arends
Overview
Explore the profile of S J Ryan Arends including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
405
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sader H, Castanheira M, Arends S, Doyle T
Antimicrob Agents Chemother
. 2025 Mar;
:e0012425.
PMID: 40047426
We evaluated the antimicrobial susceptibility of 1,400 clinical isolates of consecutively collected from United States medical centers in 2019-2023. Aztreonam-avibactam (MIC, 2/4 µg/mL; 99.6% inhibited at ≤8 µg/mL) was the...
2.
Sader H, Mendes R, Arends S, Doyle T, Castanheira M
BMC Pulm Med
. 2025 Jan;
25(1):38.
PMID: 39856702
Background: Initial antimicrobial therapy for pneumonia is frequently empirical and resistance to antimicrobial agents represents a great challenge to the treatment of patients hospitalized with pneumonia. We evaluated the frequency...
3.
Reidenberg B, Jenkins S, Crandon J, Hurlburt E, Tan X, Rhomberg P, et al.
Antimicrob Agents Chemother
. 2024 Jun;
68(7):e0038124.
PMID: 38864612
is an evolving and concerning global threat. Of particular concern are bloodstream infections related to central venous catheters. We evaluated the activity of taurolidine, a broad-spectrum antimicrobial in catheter lock...
4.
Arends S, Butler D, Scangarella-Oman N, Castanheira M, Mendes R
Diagn Microbiol Infect Dis
. 2024 Jan;
108(3):116181.
PMID: 38215519
Gepotidacin (GSK2140944) is a novel, bactericidal, first in class triazaacenaphthylene bacterial type II topoisomerase inhibitor in development for the treatment of uncomplicated urinary tract infections and gonorrhea. The performance of...
5.
Paukner S, Mendes R, Arends S, Gassner G, Gelone S, Sader H
J Antimicrob Chemother
. 2023 Dec;
79(2):360-369.
PMID: 38113528
Objectives: Lefamulin (Xenleta™), a pleuromutilin antibiotic, was approved for the oral and IV treatment of community-acquired bacterial pneumonia (CABP) in adults in 2019/2020. This study evaluated the in vitro activity...
6.
Martinez-Fructuoso L, Arends S, Freire V, Evans J, DeVries S, Peyser B, et al.
ACS Infect Dis
. 2023 May;
9(6):1245-1256.
PMID: 37163243
The continuing emergence of antibiotic-resistant microbes highlights the need for the identification of new chemotypes with antimicrobial activity. One of the most prolific sources of antimicrobial molecules has been the...
7.
Arends S, Butler D, Scangarella-Oman N, Castanheira M, Mendes R
Antimicrob Agents Chemother
. 2023 Mar;
67(4):e0152522.
PMID: 36877017
The activities of gepotidacin and comparator agents against 3,560 Escherichia coli and 344 Staphylococcus saprophyticus collected from female (81.1%) and male (18.9%) patients with urinary tract infections (UTIs) in a...
8.
Sader H, Mendes R, Arends S, Carvalhaes C, Shortridge D, Castanheira M
Int J Antimicrob Agents
. 2023 Feb;
61(4):106744.
PMID: 36738849
Objectives: To evaluate the in-vitro activity of ceftazidime-avibactam, ceftolozane-tazobactam, meropenem-vaborbactam, imipenem-relebactam and comparator agents against contemporary Pseudomonas aeruginosa isolates from US hospitals. Methods: In total, 3184 isolates were collected consecutively...
9.
Mendes R, Arends S, Streit J, Critchley I, Cotroneo N, Castanheira M
Microbiol Spectr
. 2023 Jan;
11(1):e0205722.
PMID: 36625644
Tebipenem pivoxil is an oral broad-spectrum carbapenem. This study evaluated the activity of tebipenem and comparators against UTI Enterobacterales from US hospitals (2019-2020). 3,576 Enterobacterales causing UTI in 52 centers...
10.
Sader H, Castanheira M, Carvalhaes C, Arends S, Mendes R
Microb Drug Resist
. 2022 Aug;
28(9):935-940.
PMID: 35976086
We evaluated the activity of ceftaroline against clinical isolates of ceftriaxone-nonsusceptible from United States medical centers. isolates ( = 21,750) were consecutively collected from 201 medical centers in 2008-2020 and...